Damora Therapeutics
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
75 State St Ste 100, Boston, Massachuset...Phone Number
(781) 281-9020Website
www.damoratx.comRevenue
$9.1 MillionStock Symbol
DMRAIndustry
About Damora Therapeutics
Damora Therapeutics Org Chart
Is Damora Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Damora Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Damora Therapeutics
Funding: Get notified immidiatlly once Damora Therapeutics has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Damora Therapeutics is spiking on competitors!
Check if Damora Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Damora Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Damora Therapeutics recently announced quarterly report
Click to see if Damora Therapeutics had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Damora Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Damora Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Damora Therapeutics.
Most Recent Scoops
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Damora Therapeutics
Damora Therapeutics is a Waltham, Massachusetts-based biotechnology company focused on developing a new generation of disease-modifying subcutaneous biologics for patients with mutant calreticulin (mutCALR)-driven myeloproliferative neoplasms (MPNs). The company's pipeline targets two rare blood disorders Essential Thrombocythemia (ET), a chronic c... Read More


